INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (926,4930,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(927,6077,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(928,8101,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(929,8102,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(930,14075,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(931,14076,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(932,14080,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(933,15559,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(934,16787,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(935,17956,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(936,17957,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(937,18347,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(938,19075,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(939,19077,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(940,19078,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(941,19079,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(942,19085,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(943,19630,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(944,22672,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(945,22676,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(946,22677,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(947,22679,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(948,22680,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(949,26297,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(950,28488,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (951,28489,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(952,28490,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(953,28491,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(954,28492,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(955,30008,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(956,30543,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(957,33203,'Metronidazole (topical)','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Moderate','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.','','','DDInter',0),(958,690,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(959,691,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(960,692,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(961,4210,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(962,4325,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(963,4894,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(964,4903,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(965,4904,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(966,4905,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(967,4906,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(968,4930,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(969,6077,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(970,8101,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(971,8102,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(972,14075,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(973,14076,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(974,14080,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(975,15559,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (976,16787,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(977,17956,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(978,17957,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(979,18347,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(980,19075,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(981,19077,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(982,19078,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(983,19079,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(984,19085,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(985,19630,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(986,22672,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(987,22676,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(988,22677,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(989,22679,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(990,22680,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(991,26297,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(992,28488,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(993,28489,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(994,28490,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(995,28491,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(996,28492,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(997,30008,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(998,30543,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(999,33203,'Metronidazole','Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.','alcohol','Major','Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.','','','DDInter',0),(1000,0,'Metyrosine','Metyrosine, when coadministered with other CNS depressants including alcoholic beverages, may lead to excessive somnolence and other forms of nervous system depression.','alcohol','Moderate','The patient should be informed to use caution if these agents are coadministered, especially if performing hazardous tasks such as driving or operating machinery.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1001,3846,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','grapefruit juice','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1002,3847,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','grapefruit juice','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1003,8157,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','grapefruit juice','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1004,8158,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','grapefruit juice','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1005,22734,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','grapefruit juice','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1006,30918,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','grapefruit juice','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1007,30919,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','grapefruit juice','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1008,3846,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','alcohol','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1009,3847,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','alcohol','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1010,8157,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','alcohol','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1011,8158,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','alcohol','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1012,22734,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','alcohol','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1013,30918,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','alcohol','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1014,30919,'Midazolam','The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice.  The proposed mechanism is CYP450 3A4 enzyme inhibition.  In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.  Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.','alcohol','Moderate','The manufacturer recommends that grapefruit juice should not be taken with oral midazolam.  Patients taking triazolam or alprazolam should be monitored for excessive sedation.  Alternatively, the patient could consume orange juice which does not interact with these drugs.  Patients should be advised to avoid alcohol during benzodiazepine therapy.','','','DDInter',0),(1015,0,'Midostaurin','Grapefruit juice may significantly increase the plasma concentrations of midostaurin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.','grapefruit juice','Major','The manufacturer recommends taking midostaurin with food.  Midostaurin was administered with food in clinical trials.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with midostaurin.','','','DDInter',0),(1016,0,'Mifepristone','Food may significantly increase the plasma concentrations of mifepristone.','grapefruit juice','Moderate','When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, it should be taken with food to achieve consistent plasma drug levels.  Patients should be advised to avoid consuming grapefruit or grapefruit juice during treatment with mifepristone, as it may cause increased adverse effects such as headache, dizziness, fatigue, nausea, vomiting, cramping, diarrhea, hypokalemia, adrenal insufficiency, vaginal bleeding, arthralgia, peripheral edema, and hypertension.  Because mifepristone is eliminated slowly from the body, the interaction with grapefruit juice may be observed for a prolonged period.','','','DDInter',0),(1017,0,'Mipomersen','Coadministration with alcohol may increase the risk of hepatotoxicity associated with the use of mipomersen.','alcohol','Major','Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day.','','','DDInter',0),(1018,2385,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1019,6240,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1020,15165,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1021,15166,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1022,15358,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1023,22818,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1024,22820,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1025,22821,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1026,30201,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1027,30553,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1028,32460,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1029,33813,'Mirabegron','Food reduces the oral absorption and bioavailability of mirabegron.  According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively.','high-fat foods','Minor','In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake.  Therefore, mirabegron can be taken with or without food at the recommended dosage.','','','DDInter',0),(1030,229,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1031,5890,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1032,7509,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1033,8215,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1034,11343,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1035,13593,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1036,15379,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1037,15412,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1038,19585,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1039,20186,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1040,20187,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1041,20196,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1042,20197,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1043,20210,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1044,20216,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1045,22799,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1046,22801,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1047,22802,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1048,22803,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1049,23414,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1050,24398,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1051,24743,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1052,24745,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1053,25791,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1054,25792,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1055,25811,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1056,25812,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1057,26586,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1058,33210,'Minoxidil','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1059,21947,'Miglitol','Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.','alcohol','Moderate','Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.','','','DDInter',0),(1060,21948,'Miglitol','Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.','alcohol','Moderate','Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.','','','DDInter',0),(1061,8238,'Mirtazapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1062,9826,'Mirtazapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1063,13087,'Mirtazapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1064,14323,'Mirtazapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1065,22839,'Mirtazapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1066,22841,'Mirtazapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1067,25853,'Mirtazapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1068,29838,'Mirtazapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1069,33212,'Mirtazapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1070,0,'Miltefosine','Administration of miltefosine with food may help reduce gastrointestinal adverse effects such as nausea, vomiting, abdominal pain, and diarrhea.','food','Moderate','Miltefosine should be administered with meals to help improve gastrointestinal tolerance.  Patients should be advised to contact their physician if they develop severe or persistent vomiting or diarrhea, and to drink plenty of fluids to help prevent dehydration and kidney injury.','','','DDInter',0),(1071,0,'Migalastat','Food may reduce the oral bioavailability of migalastat.  When migalastat was administered one hour before a high-fat (850 calories; 56% from fat) or light meal (507 calories; 30% from fat), or one hour after a light meal, mean migalastat peak plasma concentration (Cmax) decreased by 15% to 39% and systemic exposure (AUC) decreased by 37% to 42% compared to administration in the fasting state.','high-fat foods','Moderate','Migalastat should be taken on an empty stomach.  Patients should avoid eating for at least 2 hours before and 2 hours after taking migalastat to give a minimum 4 hours fast.  Clear liquids can be consumed during this 4-hour period.','','','DDInter',0),(1072,6693,'Milnacipran','Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.','alcohol','Moderate','Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.','','','DDInter',0),(1073,14737,'Milnacipran','Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.','alcohol','Moderate','Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.','','','DDInter',0),(1074,22757,'Milnacipran','Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.','alcohol','Moderate','Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.','','','DDInter',0),(1075,22758,'Milnacipran','Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.','alcohol','Moderate','Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1076,22759,'Milnacipran','Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.','alcohol','Moderate','Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.','','','DDInter',0),(1077,22760,'Milnacipran','Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.','alcohol','Moderate','Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.','','','DDInter',0),(1078,22761,'Milnacipran','Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.','alcohol','Moderate','Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.','','','DDInter',0),(1079,22762,'Milnacipran','Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.','alcohol','Moderate','Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.','','','DDInter',0),(1080,23184,'Milnacipran','Use of milnacipran in conjunction with chronic alcohol consumption may potentiate the risk of liver injury.  Milnacipran alone can increase serum transaminase levels.','alcohol','Moderate','Due to the risk of liver injury, patients prescribed milnacipran should be counseled to avoid excessive use of alcohol.  Milnacipran should generally not be prescribed to patients with substantial alcohol use.','','','DDInter',0),(1081,15465,'Modafinil','Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.  According to the product labeling, modafinil''s absorption may be delayed by approximately one hour if taken with food.  Similarly, the time to reach peak plasma concentration (Tmax) of armodafinil may be delayed by approximately 2 to 4 hours in the fed state.','dairy products','Minor','Modafinil should be administered at least 2 hours before (4 hours for dairy products) or 4 hours after meals.','','','DDInter',0),(1082,22882,'Modafinil','Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.  According to the product labeling, modafinil''s absorption may be delayed by approximately one hour if taken with food.  Similarly, the time to reach peak plasma concentration (Tmax) of armodafinil may be delayed by approximately 2 to 4 hours in the fed state.','dairy products','Minor','Modafinil should be administered at least 2 hours before (4 hours for dairy products) or 4 hours after meals.','','','DDInter',0),(1083,22887,'Modafinil','Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.  According to the product labeling, modafinil''s absorption may be delayed by approximately one hour if taken with food.  Similarly, the time to reach peak plasma concentration (Tmax) of armodafinil may be delayed by approximately 2 to 4 hours in the fed state.','dairy products','Minor','Modafinil should be administered at least 2 hours before (4 hours for dairy products) or 4 hours after meals.','','','DDInter',0),(1084,0,'Molindone','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1085,22796,'Moexipril','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1086,25252,'Moexipril','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1087,25253,'Moexipril','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1088,22796,'Moexipril','Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.','Food High in Potassium','Moderate','It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.','','','DDInter',0),(1089,25252,'Moexipril','Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.','Food High in Potassium','Moderate','It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.','','','DDInter',0),(1090,25253,'Moexipril','Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.','Food High in Potassium','Moderate','It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.','','','DDInter',0),(1091,8332,'Morphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1092,22989,'Morphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1093,23054,'Morphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1094,10102,'Asenapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1095,14459,'Asenapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1096,14460,'Asenapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1097,14462,'Asenapine','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1098,24196,'Mycophenolic acid','Administration of enteric coated mycophenolic acid with meals may alter its pharmacokinetics relative to administration in the fasting state.  When mycophenolic acid 720 mg was administered with a high-fat meal, there was a 33% decrease in the peak plasma concentration (Cmax); a 3.5-hour increase in delay time for the rise of plasma mycophenolic acid; and a 5-hour delay in the time to reach peak plasma concentration (Tmax).  However, no effect was observed on the systemic exposure of mycophenolic acid.','high-fat foods','Moderate','To avoid variability in drug absorption between doses, enteric coated formulations of mycophenolic acid should be taken on an empty stomach, one hour before or two hours after food intake.  The tablets should be swallowed whole and not crushed, chewed or divided in order to maintain the integrity of the enteric coating.','','','DDInter',0),(1099,0,'Nafcillin','Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.','food','Moderate','The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.','','','DDInter',0),(1100,0,'Nabilone','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1101,0,'Nadolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1102,0,'Nadolol','Coadministration with green tea may significantly decrease the plasma concentrations of nadolol.  The mechanism of interaction has not been established, but may involve inhibition of OATP1A2-mediated uptake of nadolol in the intestine by catechins in green tea.','green tea','Moderate','Based on available data, patients should be advised to limit their consumption of green tea and green tea extracts during treatment with nadolol.','','','DDInter',0),(1103,17536,'Nateglinide','Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.','alcohol','Moderate','Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.','','','DDInter',0),(1104,27465,'Nateglinide','Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.','alcohol','Moderate','Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.','','','DDInter',0),(1105,27466,'Nateglinide','Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.','alcohol','Moderate','Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.','','','DDInter',0),(1106,721,'Naltrexone','Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.','alcohol','Moderate','The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.','','','DDInter',0),(1107,3401,'Naltrexone','Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.','alcohol','Moderate','The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.','','','DDInter',0),(1108,6738,'Naltrexone','Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.','alcohol','Moderate','The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.','','','DDInter',0),(1109,6993,'Naltrexone','Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.','alcohol','Moderate','The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.','','','DDInter',0),(1110,17233,'Naltrexone','Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.','alcohol','Moderate','The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.','','','DDInter',0),(1111,25953,'Naltrexone','Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.','alcohol','Moderate','The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.','','','DDInter',0),(1112,21415,'Asparaginase Erwinia chrysanthemi','Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury.  Asparaginase-associated hepatotoxicity has been reported more commonly in adults than in children and has been strongly associated with obesity.  Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults.  Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.','alcohol','Moderate','The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins).  Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs.  Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.','','','DDInter',0),(1113,0,'Naldemedine','Grapefruit juice may increase the plasma concentrations of naldemedine.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.','grapefruit juice','Moderate','Naldemedine may be taken with or without food.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with naldemedine.','','','DDInter',0),(1114,244,'Nalbuphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1115,8548,'Nalbuphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1116,9085,'Nalbuphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1117,23220,'Nalbuphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1118,23221,'Nalbuphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1119,23223,'Nalbuphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1120,23227,'Nalbuphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1121,23228,'Nalbuphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1122,23229,'Nalbuphine','Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.','alcohol','Moderate','Concomitant use of opioid analgesics with ethanol should be avoided.','','','DDInter',0),(1123,0,'Naloxegol','Grapefruit juice may significantly increase the plasma concentrations of naloxegol.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.','grapefruit juice','Major','Patients treated with naloxegol should avoid consumption of grapefruit and grapefruit juice.  Naloxegol should be taken on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.','','','DDInter',0),(1124,4596,'Nabumetone','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1125,4597,'Nabumetone','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1126,23206,'Nabumetone','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1127,23207,'Nabumetone','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1128,23208,'Nabumetone','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1129,296,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1130,8543,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1131,8577,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1132,23200,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1133,23222,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1134,23259,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1135,23260,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1136,23261,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1137,23262,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1138,24265,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1139,27732,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1140,33251,'Naproxen','The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.','alcohol','Moderate','Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.','','','DDInter',0),(1141,8625,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1142,8781,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1143,8782,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1144,22370,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1145,22888,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1146,23332,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1147,23337,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1148,23340,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1149,23341,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1150,23342,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1151,23411,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1152,23510,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1153,23672,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1154,27798,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1155,32219,'Nebivolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1156,0,'Nefazodone','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1157,0,'Neratinib','Grapefruit, grapefruit juice, grapefruit hybrids, pomelos, star-fruit, and Seville oranges may increase the plasma concentrations of neratinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in these fruits.  Inhibition of hepatic CYP450 3A4 may also contribute.','grapefruit juice','Major','The manufacturer recommends administering neratinib with food at approximately the same time every day.  Patients should avoid consumption of grapefruit, grapefruit juice, grapefruit hybrids, pomelos, star-fruit, and Seville oranges during treatment with neratinib.','','','DDInter',0),(1158,28190,'Niacin','Ethanol can exacerbate the cutaneous flushing that is a common side effect of niacin.  At least one case of delirium and lactic acidosis has been reported with coadministration of these drugs, although data are limited.  ','alcohol','Moderate','Coadministration should probably be discouraged, particularly since chronic consumption of large amounts of alcohol is associated with hyperlipidemia.','','','DDInter',0),(1159,24646,'Nicardipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1160,24646,'Nicardipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1161,27924,'Nilotinib','Grapefruit juice may increase the plasma concentrations of nilotinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.','grapefruit juice','Major','Patients treated with nilotinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  In addition, no food should be consumed for at least 2 hours before and 1 hour after a nilotinib dose.','','','DDInter',0),(1162,27925,'Nilotinib','Grapefruit juice may increase the plasma concentrations of nilotinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.','grapefruit juice','Major','Patients treated with nilotinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  In addition, no food should be consumed for at least 2 hours before and 1 hour after a nilotinib dose.','','','DDInter',0),(1163,23973,'Nintedanib','Food enhances the oral bioavailability of nintedanib.  After food intake, nintedanib exposure increased by approximately 20% compared to administration under fasted conditions.  Absorption was also delayed, as indicated by an increase in the median time to reach maximum plasma concentration (Tmax) from 2 hours in the fasted state to approximately 4 hours under fed conditions, irrespective of the type of food ingested.','food','Moderate','Nintedanib should be administered with food.','','','DDInter',0),(1164,23974,'Nintedanib','Food enhances the oral bioavailability of nintedanib.  After food intake, nintedanib exposure increased by approximately 20% compared to administration under fasted conditions.  Absorption was also delayed, as indicated by an increase in the median time to reach maximum plasma concentration (Tmax) from 2 hours in the fasted state to approximately 4 hours under fed conditions, irrespective of the type of food ingested.','food','Moderate','Nintedanib should be administered with food.','','','DDInter',0),(1165,1064,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1166,1067,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1167,1068,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1168,1071,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1169,1073,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1170,1631,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1171,1632,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1172,11268,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1173,11270,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1174,14004,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1175,14005,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1176,14525,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1177,15164,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1178,27762,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1179,28023,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1180,28025,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1181,28026,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1182,28033,'Atenolol','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1183,1064,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1184,1067,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1185,1068,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1186,1071,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1187,1073,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1188,1631,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1189,1632,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1190,11268,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1191,11270,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1192,14004,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1193,14005,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1194,14525,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1195,15164,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1196,27762,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1197,28023,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1198,28025,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1199,28026,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0),(1200,28033,'Atenolol','Orange juice may moderately reduce the bioavailability of atenolol by interfering with its absorption from the gastrointestinal tract.','orange juice','Moderate','Patients treated orally with atenolol should be advised to take atenolol at the same time each day and to avoid consumption of large amounts of orange juice to prevent any undue fluctuations in serum drug levels.  Monitoring for altered efficacy of atenolol may be advisable.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1201,14100,'Nilutamide','Alcohol intolerance has been reported in 5% to 20% of patients following administration of nilutamide in clinical studies.  Symptoms include facial flushes, malaise, and hypotension.','alcohol','Moderate','Consumption of alcoholic beverages should be avoided in patients who experience alcohol intolerance with nilutamide.','','','DDInter',0),(1202,0,'Nisoldipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1203,0,'Nisoldipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1204,8878,'Nimodipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1205,8879,'Nimodipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1206,15461,'Nimodipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1207,19509,'Nimodipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1208,23604,'Nimodipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1209,23605,'Nimodipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1210,8878,'Nimodipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1211,8879,'Nimodipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1212,15461,'Nimodipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1213,19509,'Nimodipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1214,23604,'Nimodipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1215,23605,'Nimodipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1216,793,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1217,4037,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1218,8553,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1219,8554,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1220,8884,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1221,8885,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1222,9642,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1223,14235,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1224,16922,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1225,16923,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1226,16924,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1227,16925,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1228,16926,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1229,18121,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1230,23617,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1231,23620,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1232,23621,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1233,23622,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1234,25435,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1235,28592,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1236,28593,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1237,28594,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1238,28743,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1239,28744,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1240,29746,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1241,30010,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1242,30011,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1243,33900,'Nitazoxanide','Food enhances the bioavailability of the pharmacologically active metabolite tizoxanide (desacetyl-nitazoxamide) from nitazoxanide administration.','food','Moderate','Nitazoxanide tablets and oral suspension were administered with food in clinical trials and are recommended to be administered with food to ensure maximal drug levels in plasma.','','','DDInter',0),(1244,3424,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1245,3425,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1246,7728,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1247,8496,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1248,8898,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1249,8902,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1250,15842,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1251,16810,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1252,19975,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1253,19976,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1254,23628,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1255,23629,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1256,23630,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1257,23631,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1258,23635,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1259,23637,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1260,23639,'Nitroglycerin','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1261,0,'Nitisinone','Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.','grapefruit juice','Moderate','Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.','','','DDInter',0),(1262,4278,'Nifedipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1263,4279,'Nifedipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1264,13459,'Nifedipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1265,23577,'Nifedipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1266,23578,'Nifedipine','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1267,4278,'Nifedipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1268,4279,'Nifedipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1269,13459,'Nifedipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1270,23577,'Nifedipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1271,23578,'Nifedipine','The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.','grapefruit juice','Moderate','The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.','','','DDInter',0),(1272,0,'Nifurtimox','Use of alcohol or products containing alcohol during therapy with nitrofurans may result in a disulfiram-like reaction in some patients.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by nitrofurans in a manner similar to disulfiram.','alcohol','Major','Consumption of alcohol is considered contraindicated during nifurtimox therapy.  To ensure maximal oral absorption, nifurtimox should be administered with food.','','','DDInter',0),(1273,23613,'Nitroprusside','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1274,23627,'Nitroprusside','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1275,0,'Atazanavir','Administration of atazanavir with food enhances oral bioavailability and reduces pharmacokinetic variability.The coefficient of variation of AUC and Cmax decreased by approximately one-half when given with either a light or high-fat meal compared to the fasting state.','high-fat foods','Moderate','To ensure maximal oral absorption, atazanavir should be administered with or immediately after a meal.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1276,4285,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','orange juice','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1277,8666,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','orange juice','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1278,8969,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','orange juice','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1279,8970,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','orange juice','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1280,9312,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','orange juice','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1281,23701,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','orange juice','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1282,23722,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','orange juice','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1283,4285,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','dairy products','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1284,8666,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','dairy products','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1285,8969,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','dairy products','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1286,8970,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','dairy products','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1287,9312,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','dairy products','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1288,23701,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','dairy products','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1289,23722,'Norfloxacin','Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.','dairy products','Moderate','Oral norfloxacin should be taken at least one hour before or two hours after a meal, milk, or other dairy products or calcium-fortified foods.','','','DDInter',0),(1290,0,'Nortriptyline','Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.','alcohol','Moderate','Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.','','','DDInter',0),(1291,2569,'Norethisterone','The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.','alcohol','Minor','Consider counseling women about this interaction which is unpredictable.','','','DDInter',0),(1292,8983,'Norethisterone','The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.','alcohol','Minor','Consider counseling women about this interaction which is unpredictable.','','','DDInter',0),(1293,16315,'Norethisterone','The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.','alcohol','Minor','Consider counseling women about this interaction which is unpredictable.','','','DDInter',0),(1294,25248,'Norethisterone','The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.','alcohol','Minor','Consider counseling women about this interaction which is unpredictable.','','','DDInter',0),(1295,27513,'Norethisterone','The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.','alcohol','Minor','Consider counseling women about this interaction which is unpredictable.','','','DDInter',0),(1296,2569,'Norethisterone','Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.','grapefruit juice','Moderate','Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.','','','DDInter',0),(1297,8983,'Norethisterone','Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.','grapefruit juice','Moderate','Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.','','','DDInter',0),(1298,16315,'Norethisterone','Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.','grapefruit juice','Moderate','Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.','','','DDInter',0),(1299,25248,'Norethisterone','Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.','grapefruit juice','Moderate','Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.','','','DDInter',0),(1300,27513,'Norethisterone','Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.','grapefruit juice','Moderate','Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1301,10188,'Octreotide','Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.','food','Moderate','Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.','','','DDInter',0),(1302,12372,'Octreotide','Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.','food','Moderate','Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.','','','DDInter',0),(1303,15062,'Octreotide','Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.','food','Moderate','Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.','','','DDInter',0),(1304,15063,'Octreotide','Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.','food','Moderate','Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.','','','DDInter',0),(1305,26499,'Octreotide','Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.','food','Moderate','Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.','','','DDInter',0),(1306,2736,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1307,2985,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1308,9201,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1309,9202,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1310,9270,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1311,16732,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1312,16733,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1313,24031,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1314,24032,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1315,24033,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1316,24137,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1317,24606,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1318,24607,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1319,31082,'Olopatadine (nasal)','Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.','alcohol','Moderate','Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.','','','DDInter',0),(1320,741,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1321,744,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1322,4331,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1323,14174,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1324,18498,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1325,18500,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1326,21783,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1327,21784,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1328,23726,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1329,23727,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1330,24018,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1331,24019,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1332,24021,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1333,24022,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1334,24023,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1335,29054,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1336,31021,'Olmesartan','Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.','alcohol','Moderate','Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.','','','DDInter',0),(1337,741,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1338,744,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1339,4331,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1340,14174,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1341,18498,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1342,18500,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1343,21783,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1344,21784,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1345,23726,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1346,23727,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1347,24018,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1348,24019,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1349,24021,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1350,24022,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1351,24023,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1352,29054,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1353,31021,'Olmesartan','Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).','Food High in Potassium','Moderate','Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.','','','DDInter',0),(1354,0,'Atovaquone','Food, particularly high-fat food, significantly enhances the oral absorption and bioavailability of atovaquone.','high-fat foods','Moderate','To ensure maximal oral absorption, atovaquone products (suspension, tablet, or in combination with proguanil) should be administered with a meal or milky drink, or enteral nutrition at the same time(s) each day.  Because plasma atovaquone concentrations have been shown to correlate with the likelihood of successful treatment and in some cases, survival, alternative therapies may be appropriate for patients who have difficulty taking atovaquone with food.','','','DDInter',0),(1355,0,'Atovaquone','Food, particularly high-fat food, significantly enhances the oral absorption and bioavailability of atovaquone.','dairy products','Moderate','To ensure maximal oral absorption, atovaquone products (suspension, tablet, or in combination with proguanil) should be administered with a meal or milky drink, or enteral nutrition at the same time(s) each day.  Because plasma atovaquone concentrations have been shown to correlate with the likelihood of successful treatment and in some cases, survival, alternative therapies may be appropriate for patients who have difficulty taking atovaquone with food.','','','DDInter',0),(1356,1088,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1357,1089,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1358,1090,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1359,1094,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1360,1095,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1361,1097,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1362,1678,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1363,4008,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1364,4009,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1365,4735,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1366,7349,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1367,7350,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1368,7352,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1369,7355,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1370,7359,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1371,7372,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1372,7397,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1373,7398,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1374,7399,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1375,11556,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0);
INSERT OR REPLACE INTO food_interactions (id,med_id,trade_name,interaction,ingredient,severity,management_text,mechanism_text,reference_text,source,created_at) VALUES (1376,13234,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1377,13512,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1378,14227,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1379,14228,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1380,14563,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1381,14570,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1382,15442,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1383,16266,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1384,18869,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1385,21870,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1386,21882,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1387,21884,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1388,21885,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1389,21887,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1390,21889,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1391,21890,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1392,21891,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1393,21893,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1394,21894,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1395,21905,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1396,21906,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1397,21907,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1398,21915,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1399,21916,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0),(1400,21935,'Atorvastatin','Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.','alcohol','Moderate','Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.','','','DDInter',0);
